Skip to content Skip to footer

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front 

Shots :Coherus signs an agreement with Sandoz to divest its ophthalmology franchise which includes a lead asset Cimerli (ranibizumab-eqrn) along with its supporting commercial infrastructure As per the terms of the agreement, Coherus will receive an all-cash consideration of $170M as up-front payment along with an additional amount for Cimerli product inventory &…

Read more